News

Filter

Current filters:

MabTheraBenlysta

GlaxoSmithKline/HGS's Benlysta will push SLE drug market to more than $1.6 billion in 2019

10-08-2010

Driven primarily by the launch and uptake of Human Genome Sciences and GlaxoSmithKline's Benlysta (belimumab),…

Anti-Arthritics/RheumaticsBenlystaGlaxoSmithKlineHuman Genome SciencesMabTheraMarkets & MarketingPharmaceuticalRituxan

Back to top